Comparative Pharmacology
Head-to-head clinical analysis: ANADROL 50 versus WINSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANADROL 50 versus WINSTROL.
ANADROL-50 vs WINSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anabolic steroid; binds to androgen receptors, increasing protein synthesis and promoting nitrogen retention, leading to muscle growth and erythropoietin production.
Winstrol (stanozolol) is an anabolic steroid derived from dihydrotestosterone. It binds to androgen receptors, increasing protein synthesis and inhibiting catabolic glucocorticoid activity, leading to enhanced muscle growth and reduced inflammation.
Adults: 50-200 mg orally once daily for 2-6 weeks, then 2-4 weeks off. Not for continuous use.
Adults: 2 mg orally three times daily, or 50 mg/mL intramuscularly once monthly (3-4 week intervals) for anabolic effect. Dose range: 1-3 mg/kg/day for hereditary angioedema.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours for parent drug; active metabolite 17α-methyl-5α-androstan-3α,17β-diol has half-life ~12-18 hours. Requires multiple daily dosing.
Terminal elimination half-life: 9-10 hours for oral administration (stanozolol); parenteral (IM) half-life extends to ~24 hours due to slow release from injection site. Clinical context: supports once-daily oral dosing or weekly IM dosing.
Primarily renal: 90% as glucuronide and sulfate conjugates; 6% fecal; <3% unchanged.
Primarily renal: 90% as metabolites (glucuronide and sulfate conjugates) and 10% as unchanged drug; minor biliary/fecal elimination (<5%).
Category C
Category C
Anabolic Steroid
Anabolic Steroid